VERSUS // BPC-157 vs TB-500
BPC-157 TB-500 is a two-peptide research blend, racked corner-against-corner with every study and the access record.
Two distinct peptides. Two distinct mechanisms. One honest scorecard of what the literature established for each, and where the combination has no match on record.
The Wolverine blend is a matchup, not a molecule
BPC-157 TB-500 is the research-community name for a two-peptide pairing: BPC-157 in one corner, TB-500 in the other. It is not a single chemical entity. It has no combined molecular weight, no CAS number, and no shared structure — only two synthetic peptides racked together and marketed as a tissue-repair "stack."
BPC-157 is a 15-amino-acid pentadecapeptide, sequence GEPPPGKPADDAGLV, about 1,419 Da, derived from a protein found in human gastric juice. Its move is local: a cytoprotective and pro-angiogenic signal that up-regulates VEGFR2 with a downstream Akt-eNOS cascade [2]. In transected rat Achilles tendons it improved load-to-failure, collagen organization, and tendon integrity against untreated controls, and in culture it flipped 4-hydroxynonenal-suppressed tendocytes back into growth [1].
TB-500 is a different fighter entirely — a synthetic N-acetylated 7-mer, Ac-LKKTETQ, about 889 Da, corresponding to the actin-binding region (residues 17-23) of the 43-residue protein Thymosin Beta-4. Its move is intracellular: the LKKTETQ helix binds one molecule of monomeric G-actin in a 1:1 complex and caps it, regulating the cytoskeletal dynamics that drive cell migration [3]. The crystal structure of that complex established the capping mechanism at 2 angstroms [3].
The pairing reads cleanly as a head-to-head because the two peptides work through largely non-overlapping pathways. That is also the entire basis of the "synergy" claim — and the place where the marketing outruns the evidence. No controlled combination study has ever defined a synergy ratio, dose, or endpoint for the two given together [8]. This site reads each corner against its own studies, then shows the combination row for what it is: empty.
BPC-157 and TB-500: the two peptides in the Wolverine blend
BPC-157 and TB-500 are the two constituents that make the blend a matchup. The table below racks them corner against corner — same fields, two fighters — so the distinction is legible at a glance.
BPC-157 (blue corner) is the cytoprotective and angiogenic signal. Reported pathways: VEGFR2 up-regulation and internalization driving a VEGFR2-Akt-eNOS pro-angiogenic relay [2]; nitric-oxide-system and Src-Caveolin-1-eNOS vasomotor signaling [5]; growth-hormone-receptor up-regulation with FAK-paxillin signaling in tendon fibroblasts [1].
TB-500 (red corner) is the cytoskeletal, cell-migration signal. Its LKKTETQ motif sequesters monomeric G-actin 1:1 [3], and the parent protein Thymosin Beta-4 is reported to promote cell migration, reduce myofibroblast number, limit post-injury inflammation, and drive angiogenesis through endothelial migration [4].
A caveat rides under the red corner throughout: most efficacy data attributed to "TB-500" were generated with full-length Thymosin Beta-4 (about 4,963 Da), not the 889 Da Ac-LKKTETQ heptapeptide that is actually sold [7]. The blend inherits that gap. You can read the BPC-157 vs TB-500 mechanisms corner by corner, or jump to the BPC-157 and TB-500 angiogenesis research where the two routes converge on one repair process.
What is the Wolverine peptide blend?
What is the Wolverine peptide blend?
The Wolverine peptide blend is a research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair "stack." It is not a single chemical entity and not an approved product. The search term "wolverine peptide" carries roughly 14,800 searches a month, but that volume is heavily conflated with the comic-book character — the substance under discussion here is strictly the BPC-157 plus TB-500 pairing.
What is BPC-157 and TB-500?
BPC-157 and TB-500 are two distinct synthetic peptides combined as a research blend. BPC-157 is a 15-amino-acid cytoprotective and angiogenic peptide (GEPPPGKPADDAGLV, ~1,419 Da). TB-500 is an N-acetylated 7-mer (Ac-LKKTETQ, ~889 Da) from the actin-binding region of Thymosin Beta-4. Different sequences, different sizes, different mechanisms — paired, not fused.
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid gastric-juice-derived cytoprotective and angiogenic peptide that acts locally through VEGFR2-Akt-eNOS signaling [2]. TB-500 is a 7-amino-acid actin-binding fragment of Thymosin Beta-4 that acts intracellularly on cytoskeletal migration through 1:1 G-actin sequestration [3]. Different sequences, different mechanisms, different corners.
Read this scorecard before any other source
The headline of this matchup is the empty row. Both fighters carry real, citable preclinical movesets — and the combination they are sold as has no controlled human trial, no defined synergy ratio, and no validated dose [8]. A 2025 systematic review of BPC-157 in orthopaedic sports medicine pulled 36 studies, found only one was human, reported no clinical safety data, rated the evidence at the lowest tiers, and made no mention of TB-500 or any blend at all [8].
Neither constituent is FDA-approved for human use. The FDA placed both BPC-157 and the "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in Category 2 for 503A compounding — bulk substances it identified as possibly presenting significant safety risks — effective with its September 29, 2023 list update [11]. Both are also prohibited by the World Anti-Doping Agency. The full picture sits in the Wolverine legal status and 503A compounding record.
From here, work through the corners: the combination-rationale and synergy claim, the two-route BPC-157 and TB-500 angiogenesis research, the studied research doses (animal models), the frequently asked questions about the blend, and the full reference list.